Impact of esomeprazole and vonoprazan on the antiplatelet effect of clopidogrel and prasugrel, with reference to CYP2C19 genotypes

Trial Profile

Impact of esomeprazole and vonoprazan on the antiplatelet effect of clopidogrel and prasugrel, with reference to CYP2C19 genotypes

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Clopidogrel (Primary) ; Esomeprazole (Primary) ; Prasugrel (Primary) ; Vonoprazan (Primary)
  • Indications Duodenal ulcer; Gastric ulcer; Ischaemic heart disorders; Reflux oesophagitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Sep 2017 Results published in the Clinical Pharmacology and Therapeutics
    • 07 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 18 May 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top